Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Medical Oncology
What factors into your decision about whether to use HIPEC for advanced ovarian cancer?
Related Questions
For a patient with locally current endometrial cancer whose disease had complete radiographic response to carboplatin, Taxol, and pembrolizumab, would you consider adding radiation therapy?
Do you have concerns about the validity of the INTERLACE data, considering the long study recruitment period (10 years) and evolution of radiation techniques that have occurred during that time frame?
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
What does bevacizumab contribute in metastatic cervical cancer when used in combination with a platinum doublet + pembrolizumab?
For an elderly woman with a platinum-resistant recurrence of a high-grade serous ovarian cancer who has been rendered NED surgically, is observation a reasonable approach?
Have you had patients who wish to take ivermectin and/or fenbendazole as adjunct treatments for gynecologic cancers, and if so, how have you handled this?
What strategies do you find helpful in advanced care planning with patients/families who are very "miracle" centered?
When utilizing KN-A18 protocol, how do you best address symptoms of colitis/cystitis?
What is your experience with in vitro chemosensitivity testing?
Between KEYNOTE A-18 and INTERLACE, for which patients would you recommend using one protocol over another?
